
    
      This is a randomized, double-blind, parallel group study comparing two doses of INT131( 3 mg
      and 1 mg) administered orally (PO) daily (QD) versus placebo 1 tablet PO QD in subjects with
      treatment-naïve RRMS for ≤ 3 years..

      Part 2 of the study is open-label, Subjects completing 6 months of evaluations and study drug
      in Part 1 without serious study drug-related treatment emergent adverse events (TEAE) will be
      switched to INT131 1 mg PO QD and followed for an additional 6 months.
    
  